News GSK pushes 'next-generation' mRNA flu shot into phase 3 Buoyed by positive data in a phase 2 trial, GSK will start a phase 3 programme for an mRNA-based flu shot targeting both HA and NA flu antigens.
News Moderna's Q1 revenues rocket, thanks to ex-US sales Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.
News Pivotal trial of Moderna's H5N1 bird flu jab gets underway The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu have received shots in the UK and US.
News Moderna closes on EU approval for combined flu/COVID jab Moderna's combined vaccine for both flu and COVID-19 has been recommended for approval in the EU, after being knocked back in the US.
News FDA relents and will review Moderna's flu shot The FDA will start a review of Moderna's flu jab mRNA-1010, after refusing to accept the filing last week, with a new "regulatory approach."
News FDA says comparator dose scuppered Moderna's flu jab filing The FDA has defended its decision to issue a refusal-to-file (RTF) letter for Moderna's new mRNA-based influenza vaccine.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.